Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIR2501 in ALS and paclitaxel-associated CIPN risk
ACTRN12626000441314Phase 2Recruiting
- Sponsor
- Sironax
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of SIR2501 in amyotrophic lateral sclerosis (ALS) and chemotherapy-induced peripheral neuropathy (CIPN) (4 arms), sponsored by Sironax. Primary endpoints: Incidence of dose-limiting toxicities, Change in Amyotrophic Lateral Sclerosis Functional Rating Scale Revised score and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
SIR2501
03
Conditions
amyotrophic lateral sclerosis (ALS)chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on ACTRN12626000441314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000441314.